Search
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalOver 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.
Acriflavine
go.drugbank.com/drugs/DB13373InvestigationalCategories: Compounds used in a research, industrial, or household settingNizofenone
go.drugbank.com/drugs/DB13546ExperimentalCategories: Compounds used in a research, industrial, or household settingVX-148
go.drugbank.com/drugs/DB06103ExperimentalThe IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases. … VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).
SR-123781A
go.drugbank.com/drugs/DB05361InvestigationalSR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Umbilical Cord Blood Hematopoietic Stem Cells
go.drugbank.com/drugs/DB15723InvestigationalFrom the UCB, mononuclear cells are isolated and cultured in medium, expanded, and differentiated into the desired cell type. … Specifically, the proliferation capacity of human umbilical cord blood mononuclear progenitor cells (HUCBC) are much higher than similar cells in bone marrow.
ATL1102
go.drugbank.com/drugs/DB04997InvestigationalATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.